Form 4: CEO Birgit Girshick Reports CRL Stock Transactions
Statement of Changes in Beneficial Ownership
Charles River Laboratories CEO Birgit Girshick reported the disposition of common stock to cover tax obligations related to equity vesting.
Summary
- CEO Birgit Girshick disposed of 376 shares of common stock on 05/26/2026 at a price of $160.30.
- CEO Birgit Girshick disposed of 242 shares of common stock on 05/27/2026 at a price of $156.73.
- The transactions were executed to satisfy tax withholding obligations associated with the vesting of equity awards.
- Following these transactions, the CEO maintains direct ownership of 31,020 shares and indirect ownership of 40,417 shares via a revocable trust.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative event, as the share reduction is purely for tax compliance and does not reflect a change in the CEO's outlook on the company.
Positives
- The transactions were routine tax-related dispositions rather than discretionary sales, indicating continued long-term alignment with company performance.
Negatives
- Reduction in direct share ownership by the CEO, though the volume is immaterial relative to total holdings.
Risks
- Market volatility affecting the value of executive equity holdings.
- Regulatory and tax compliance risks associated with equity compensation plans.
Future Outlook
No forward-looking guidance or strategic outlook provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that tax-related share withholding is a standard administrative practice for executives at large-cap life sciences firms like Charles River Laboratories and does not typically signal a change in management sentiment.
Comparison to Industry Standards
- The transaction follows standard industry practices for executive compensation tax withholding at peer companies such as Thermo Fisher Scientific and IQVIA.
Stakeholder Impact
- Minimal impact on shareholders as the transaction is a standard tax-withholding event.
Key Dates
| Date | Description |
|---|---|
| 05/26/2026 | Transaction date for the disposition of 376 shares. |
| 05/27/2026 | Transaction date for the disposition of 242 shares and filing date. |
Keywords
Charles River Laboratories, CRL, Insider Trading, Form 4, Executive Compensation, Birgit Girshick
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.